Background
Various neurological manifestations have been described in relation to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and coronavirus disease 2019 (COVID‐19). However, the development of cerebellar ataxia after recovery from COVID‐19 is rare. We present a case of cerebellar ataxia 3 weeks after recovery from COVID‐19.
Case Presentation
A 70‐year‐old male patient from an urban area of India presented with ataxia. He was hypertensive and had been receiving treatment for post‐traumatic epilepsy for the previous 3 years. He had previously had laboratory‐confirmed COVID‐19 infection with mild symptoms that resolved within 2 weeks. However, 3 weeks after symptom improvement, he developed severe pan‐cerebellar ataxia. Investigations were suggestive of post‐infectious cerebellar ataxia. Other causes of ataxia were excluded. He responded well to pulse methylprednisolone therapy and was discharged with mild tremor and ataxia.
Conclusion
Post‐infectious cerebellar ataxia is an unusual presentation after COVID‐19. The clinician should be aware of such complications following COVID‐19 infection as early diagnosis and proper management leads to better outcomes in many patients.
Cerebral venous thrombosis (CVT) is a rare clinical entity, with clinical presentations extending from headache and seizures to coma and death. For adults developing progressive neurological worsening despite adequate medical management, endovascular thrombolysis and/or mechanical thrombectomy may be considered as treatment options. We present one such patient with CVT who developed seizures and slipped into a coma, despite best medical management. A large-bore aspiration catheter was used as a standalone system for the endovascular procedure. The venous sinuses were successfully re-canalized. The patient was discharged a week later with a modified Rankin scale of 2. Studies show that endovascular thrombolysis used alone or in conjunction with thrombectomy for CVT has a higher risk of hemorrhagic complications. If we were to use mechanical thrombectomy devices (that are specifically designed for intracranial clot retrieval) as a stand-alone system, we would probably have better clinical outcomes with a lower risk of hemorrhagic complications.
In the originally published version of this article, there were some missing contents in the Ethics Statement section, which should be properly revised as follows:
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.